Welcome to our dedicated page for Chemomab Therapeutics Ltd. American Depositary Share news (Ticker: CMMB), a resource for investors and traders seeking the latest updates and insights on Chemomab Therapeutics Ltd. American Depositary Share stock.
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology company focused on the development of innovative therapeutics to treat fibro-inflammatory diseases with significant unmet medical needs. The company's proprietary platform centers on CM-101, a first-in-class monoclonal antibody that targets the protein CCL24, a key regulator of inflammatory and fibrotic pathways in several severe diseases.
CM-101 has demonstrated potential in disrupting the underlying biology of fibrosis through a novel mechanism of action. The company is actively advancing CM-101 through multiple Phase 2 clinical trials aimed at treating rare and life-threatening conditions such as primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), and systemic sclerosis (SSc). In recognition of its innovative approach, CM-101 has been granted Orphan Drug designation in both the U.S. and the European Union, and it recently received Fast Track designation from the FDA for PSC treatment.
Chemomab has reported encouraging preliminary results from these trials, which indicate that CM-101 is safe and effective in interfering with fibrotic and inflammatory pathways. The company has secured robust intellectual property protections for CM-101, with patents granted or pending in major territories worldwide, ensuring proprietary rights for the treatment of multiple indications until at least 2038.
Recent highlights from Chemomab include:
- Completion of patient enrollment in the Phase 2 PSC trial, with topline data expected mid-2024.
- Granting of new patents in Brazil, Israel, and Europe that further protect the use of CM-101 in treating liver diseases and other conditions.
- Publication of peer-reviewed studies validating the role of CCL24 in driving PSC and SSc pathologies, and the potential of CM-101 as a therapeutic intervention.
- Presentations at major scientific conferences including EASL 2024 and the Gordon Research Conference, showcasing novel translational assays and proteomic profiling studies that support the efficacy of CM-101.
As Chemomab continues to advance its clinical programs and expand its scientific understanding of fibro-inflammatory diseases, it remains committed to addressing the urgent need for effective treatments in these challenging medical areas.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory disease treatments, announced it will release its Q3 2024 financial results and business update on November 14, 2024, at 7:00 am ET. Investors interested in discussing the results after the release can contact the company via IR@chemomab.com.
Chemomab Therapeutics (Nasdaq: CMMB) announced that its late-breaking abstract on the Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis (PSC) has been selected for an oral presentation at the AASLD The Liver Meeting® 2024. The conference will be held in San Diego from November 15-19, 2024.
Professor Christopher Bowlus, MD, FAASLD, from the University of California Davis School of Medicine, will present the data from the double-blinded portion of the trial. The presentation, titled 'CM-101 improved fibrosis biomarkers in patients with primary sclerosing cholangitis: The Phase 2 SPRING Study', is scheduled for November 18, 2024, from 2:45-3:00pm PT during the Late Breaking Abstract Parallel Session 1.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on fibro-inflammatory diseases, has announced its participation in two upcoming investor conferences. The company will attend the Third Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York City, where management will meet with investors. Additionally, CEO Dr. Adi Mor will participate in a fireside chat at the Maxim Healthcare Virtual Summit on October 16, 2024, at 9:00 am ET.
The ROTH conference will feature one-on-one meetings with investors, while the Maxim Healthcare Summit will include a virtual fireside chat. A recording of the Maxim Summit fireside chat will be made available on Chemomab's investor relations website after the event. Both conferences are invitation-only events.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on fibro-inflammatory diseases, has announced upcoming investor conference presentations. CEO Dr. Adi Mor will deliver corporate presentations at two events:
1. H.C. Wainwright 26th Annual Global Investment Conference: A prerecorded webcast available from September 9, 2024, at 7:00 am ET for 90 days.
2. HBM Biopharma Summit 2024 in Zurich, Switzerland: A live in-person presentation scheduled for September 23, 2024, at 10:45 am CET at the Park Hyatt Zurich.
The H.C. Wainwright presentation will be accessible via webcast, while the HBM Summit presentation will not be webcast. These presentations offer investors insights into Chemomab's innovative therapeutics for high unmet need fibro-inflammatory diseases.
Chemomab Therapeutics (Nasdaq: CMMB) reported positive Phase 2 results for CM-101 in Primary Sclerosing Cholangitis (PSC), demonstrating safety and anti-fibrotic, anti-inflammatory, and anti-cholestatic activity. The company completed a $10 million PIPE financing, extending its cash runway through early 2026. Key highlights include:
- CM-101 met primary and secondary endpoints in the SPRING trial
- First therapy to show broad effects on PSC's main components
- Statistically significant reduction in liver stiffness after 15 weeks
- Planning for Phase 3 PSC trial and FDA discussions
- Q2 2024 financials: $12.8 million cash position, $2.9 million R&D expenses, $0.8 million G&A expenses
- Net loss of $3.6 million or $0.01 per share
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, has announced that it will release its second quarter 2024 financial results on August 21, 2024, at 7:00 am Eastern Time. The company will also provide a business update along with the financial report. Investors interested in discussing the financial results or business update after the earnings release can contact the company at IR@chemomab.com.
Chemomab Therapeutics (Nasdaq: CMMB) has successfully closed a $10 million private placement, extending its cash runway potentially to early 2026. The financing, which involved both existing and new investors including HBM Healthcare Investments, OrbiMed, and Sphera Biotech Master Fund LP, positions the company to achieve key clinical milestones in Q1 2025 while advancing discussions with potential partners based on positive Phase 2 results.
The private placement involved the sale of 8,097,167 ADSs and pre-funded warrants at a price of $1.235 per ADS, without warrant coverage. Oppenheimer & Co. Inc. acted as Capital Markets Advisor, with LifeSci Capital and Maxim Group also advising. The company has agreed to file a registration statement with the SEC for the resale of the issued securities.
Chemomab Therapeutics (Nasdaq: CMMB), a clinical-stage biotech company focusing on fibro-inflammatory diseases, has regained compliance with Nasdaq's minimum bid price requirement. The company received a notification letter from Nasdaq confirming that it has met the closing bid price of $1.00 or greater for 10 consecutive business days from July 9 to July 22, 2024. This resolves the non-compliance issue initially reported on November 6, 2023, when Chemomab's American Depositary Shares (ADSs) had fallen below the $1.00 threshold for more than 30 consecutive business days. With this development, Nasdaq has closed the matter, affirming Chemomab's continued listing on the exchange.
Chemomab Therapeutics (Nasdaq: CMMB) has announced a $10 million private placement (PIPE) with participation from new and existing investors. The company is selling 4,188,867 American Depositary Shares at $1.235 per share and pre-funded warrants to purchase up to 3,908,300 ADSs. This funding is expected to extend Chemomab's cash runway through early 2026, supporting operations for about a year after two major milestones anticipated in early 2025.
The proceeds will be used to fund development programs for CM-101, their innovative therapeutic for fibro-inflammatory diseases, as well as general corporate purposes. The PIPE is set to close around July 26, 2024, subject to customary closing conditions. Oppenheimer & Co. Inc. is acting as Capital Markets Advisor for the transaction.
Chemomab Therapeutics (Nasdaq: CMMB) has reported positive topline results from its Phase 2 SPRING trial of CM-101, a first-in-class monoclonal antibody, in patients with primary sclerosing cholangitis (PSC). The trial met its primary endpoint of safety and tolerability and demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across multiple secondary efficacy endpoints.
Key findings include:
- Statistically significant improvement in liver stiffness, a important PSC disease marker
- Reduction in total bilirubin, an important marker of cholestasis and liver health
- Improvements in pruritis, a cholestatic indicator relevant to patients
- Favorable safety profile and general tolerability over the 15-week treatment period
The company plans to advance CM-101 to a Phase 3 PSC trial in 2025, following discussions with the FDA later this year.
FAQ
What is the current stock price of Chemomab Therapeutics Ltd. American Depositary Share (CMMB)?
What is the market cap of Chemomab Therapeutics Ltd. American Depositary Share (CMMB)?
What is Chemomab Therapeutics Ltd.?
What is CM-101?
What diseases is CM-101 being tested for?
Has CM-101 received any special designations from regulatory authorities?
When are the results from the Phase 2 PSC trial expected?
What recent achievements has Chemomab announced?
What makes CM-101 unique?
What is the significance of the new patents granted to Chemomab?
Where has Chemomab presented its research?
How does CM-101 work?
